NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, June 10, 2023

Register Now

7:30am – 4:00pm 

Earn up to 6.75 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Location

Hyatt Regency Cleveland At The Arcade
420 Superior Ave, Cleveland, OH 44114

Providers

Jointly Provided by UH Seidman Cancer Center, University Hospital, Case Western Reserve University, and the North American Neuroendocrine Tumor Society

Course Directors

Amr Mohamed, MD, UH Seidman Cancer Center, University Hospital

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

• • Amr Mohamed, MD, Associate Professor and Director of the Neuroendocrine Tumor Program, UH Seidman Cancer Center, University Hospitals

• • Background, Epidemiology, etc; Pathologic Principles, Differentiation, Grading
    Sylvia Asa, MD, PhD, Clinical Professor, Department of Pathology, School of Medicine, Case Western Reserve University
  • Anatomic Imaging
    Sree Harsha Tirumani, MD, Clinical Associate Professor, Department of Radiology, Case Western Reserve University
  • Functional Imaging
    Riham El Khouli, MD, PhD, Associate Professor of Radiology, University of Kentucky
  • Endoscopic Diagnosis
    Amy Hosmer, MD, Gastroenterologist, UH Digestive Health Institute

• • Surgical principles in localized NETs: SBNETs and PNETs; Intraoperative management of Carcinoid Crisis
    Lee Ocuin, MD, Clinical Assistant Professor, Department of Surgery, Case Western Reserve University
  • Surgery for Gastric, Duodenal, and Hind Gut NETs
    Eric Liu, MD, FACS, Surgical Director, Neuroendocrine Institute, Rocky Mountain Cancer Centers
  • Principles of Cytoreduction: Hepatic and extra-hepatic; Resection of primary tumor in Stage IV Disease
    J. Philip Boudreaux, MD, FACS, Professor of Surgery, Division of Surgical Oncology, LSU Health Sciences Center

• • Somatostatin Analogs; Targeted drugs (e.g. everolimus, sunitinib…etc); Role of Cytotoxic Chemotherapy
    Bahar Laderian, MD, Medical Oncologist, Cleveland Clinic

• • Role of PRRT; Risks and contraindications
    Thorvardur (Thor) R. Halfdanarson, MD, Professor, Mayo Clinic School of Medicine
  • Clinical trials/emerging treatments for GEP-NETs
    Amr Mohamed, MD, Associate Professor and Director of the Neuroendocrine Tumor Program, UH Seidman Cancer Center, University Hospitals

• • Hormonal Syndromes and Symptom Control
    Lauren Fishbein, MD, PhD, Associate Professor, University of Colorado

• • Jon Davidson, MD, FSIR, Division Chief, Department of Interventional Radiology, University Hospitals Health System, Case Western Reserve University School of Medicine

• • So Yeon Kim, MD, Assistant Professor, Yale School of Medicine

• • Amr Mohamed, MD, Associate Professor and Director of the Neuroendocrine Tumor Program, UH Seidman Cancer Center, University Hospitals
  • Lauren Fishbein, MD, PhD, Associate Professor, University of Colorado
  • Eric Liu, MD, FACS, Surgical Director, Neuroendocrine Institute, Rocky Mountain Cancer Centers
  • J. Philip Boudreaux, MD, FACS, Professor of Surgery, Division of Surgical Oncology, LSU Health Sciences Center

 Register Now

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Register Now

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before May 5, 2023. On or after May 6, 2023, no refund will be made.

UH Seidman Cancer Center, University Hospital, Case Western Reserve University and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.